Châtillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in...

Châtillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in...

DBV submits VIASKIN Peanut Patch for FDA approval following positive Phase 3 results in peanut-allergic children ages 4 through 7.

Reported Tuesday, Sep 29 - 6:31pm EDT (TheFly subscription required to read more.)

DBV Technologies nimmt 50 Mio. Dollar durch Aktienplatzierung ein. Die Mittel fließen in die Entwicklung des Allergie-Pflasters Viaskin.

The food allergy market landscape is advancing through a robust clinical pipeline, with key programs being developed by companies such as DBV Technologies (Viaskin [DBV712] Peanut Patch), Novartis (Remibrutinib), Aravax (PVX108), ALK-Abelló (Sublingual Immunotherapy Tablet), InnoUp Farma...

DBV Technologies (Nasdaq: DBVT) reported second quarter and half-year 2026 results, highlighting continued regulatory progress for the VIASKIN® Peanut Patch in children aged 4–7 years. The company is engaged in detailed, ongoing interactions with the FDA and now anticipates submitting its BLA in the third quarter of 2026, with no additional data requested to date.DBV closed enrollment in the COMFORT Toddlers safety study, initiated the THRIVE study in infants, and remains funded into the third quarter of 2027, supported by $174.9 million in cash and cash equivalents at June 30, 2026. For the first half of 2026, operating income was $1.6 million, operating expenses $100.1 million, and net loss $98.0 million, or $(0.23) per share, compared with a $(0.58) loss per share a year earlier. Net cash used in operating and investing activities rose to $102.6 million, reflecting increased clinical, manufacturing, and commercial readiness investments.

DBV Technologies will submit its Viaskin Peanut FDA application in late 2026 after agreeing to include additional safety data.

DBV Technologies will submit its Viaskin Peanut FDA application in late 2026 after agreeing to include additional safety data.

Reported Tuesday, Jun 30 - 5:57am EDT (TheFly subscription required to read more.)

Reported Monday, Jun 29 - 4:02pm EDT (TheFly subscription required to read more.)

New VITESSE subgroup analysis shows VIASKIN Peanut Patch hit significance across asthma, food allergy and atopic dermatitis co-morbidities in children.

DBV Technologies has screened the first participant in a pioneering trial of its peanut allergy patch for infants.

DBV Technologies (Nasdaq: DBVT) reported the first participant screened in THRIVE, a Phase 2, single-arm, open-label study of the VIASKIN Peanut Patch in infants 6–12 months with peanut allergy.Infants receive daily patch treatment for 36 months, followed by a 12‑month period assessing ad lib peanut consumption.

DBV Technologies (NASDAQ:DBVT) reported Q1 2026 results with $229M cash as of March 31, 2026, funding operations into Q2 2027 after full exercise of PIPE warrants.Q1 results show net loss $47.6M and increased R&D and SG&A spending as the company advances BLA submissions for VIASKIN® Peanut Patch and commercial readiness in the U.S.

DBV Technologies (Nasdaq: DBVT) reported full year 2025 results and a business update focused on advancing VIASKIN® Peanut Patch clinical programs for ages 1–7 and preparing for BLA submissions.Key facts: positive Phase 3 VITESSE topline, 2025 PIPE and ATM financings, $194.2M cash at 12/31/2025 plus $94M received January 2026, and cash runway into Q2 2027.

DBV Technologies' VITESSE trial showed Viaskin Peanut patch effectively increases peanut tolerance in children, supporting their upcoming submission for approval to the FDA.

DBV Technologies' VITESSE trial showed Viaskin Peanut patch effectively increases peanut tolerance in children, supporting their upcoming submission for approval to the FDA.

DBV Technologies reveals new VITESSE Phase 3 data at AAAAI 2026: 83% of kids on VIASKIN Peanut Patch increased safe peanut dose vs 48% on placebo, with excellent safety.

Châtillon, France, February 28, 2026 DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting Approximately 83% of children treated with the VIASKIN ® Peanut Patch increased their eliciting dose at month 12, compared to approximately 48% in

${dotPageContent.seodescription}

DBV Technologies (NASDAQ:DBVT) announced €166.7 million of gross proceeds from the full exercise of ABSA Warrants and BS Warrants issued in its March 2025 financing, resulting in issuance of 59,657,507 new shares and 71,005,656 second pre-funded warrants.Proceeds, together with existing cash, are intended to fund working capital, preparation/submission of a potential BLA and launch readiness for VIASKIN Peanut in children 4–7 in the U.S., if approved. The company estimates these funds support operations for at least 12 months and sees no substantial doubt about going concern as of the press release date.